Many of those, such as non-small cell lung cancer, metastatic breast cancer and melanoma do not currently have effective conventional therapies, making BRD4 inhibition a very promising option by default [19,20,21,22,23]. Here, BRD4 is linked to non-small cell lung carcinoma.